Gland Pharma [GLAND] vs Lupin [LUPIN] Detailed Stock Comparison

Gland Pharma Ltd.

NSE
Loading...

Lupin Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Gland Pharma Ltd. wins in 5 metrics, Lupin Ltd. wins in 15 metrics, with 0 ties. Lupin Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Gland Pharma Ltd. Lupin Ltd. Better
P/E Ratio (TTM) 34.86 22.74 Lupin Ltd.
Price-to-Book Ratio 3.09 5.37 Gland Pharma Ltd.
Debt-to-Equity Ratio 3.16 31.51 Gland Pharma Ltd.
PEG Ratio 0.58 0.60 Gland Pharma Ltd.
EV/EBITDA 18.80 15.38 Lupin Ltd.
Profit Margin (TTM) 13.86% 17.76% Lupin Ltd.
Operating Margin (TTM) 19.30% 26.46% Lupin Ltd.
EBITDA Margin (TTM) 19.30% 26.46% Lupin Ltd.
Return on Equity 7.63% 18.98% Lupin Ltd.
Return on Assets (TTM) 6.22% 11.24% Lupin Ltd.
Free Cash Flow (TTM) $5.21B $13.18B Lupin Ltd.
Dividend Yield 1.95% 0.62% Gland Pharma Ltd.
1-Year Return 33.88% 14.69% Gland Pharma Ltd.
Price-to-Sales Ratio (TTM) 4.84 4.03 Lupin Ltd.
Enterprise Value $266.81B $1,054.33B Lupin Ltd.
EV/Revenue Ratio 4.37 4.03 Lupin Ltd.
Gross Profit Margin (TTM) 65.99% 73.55% Lupin Ltd.
Revenue per Share (TTM) $371 $573 Lupin Ltd.
Earnings per Share (Diluted) $51.50 $101.47 Lupin Ltd.
Beta (Stock Volatility) 0.41 0.28 Lupin Ltd.

Gland Pharma Ltd. vs Lupin Ltd. Stock Performance Analysis

Loading Price Chart...

GLAND
LUPIN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Gland Pharma Ltd.-2.31%-1.82%18.29%37.34%32.35%28.86%
Lupin Ltd.-0.88%0.83%-0.14%-0.76%8.63%8.10%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Gland Pharma Ltd.33.88%124.19%-26.40%24.33%24.33%24.33%
Lupin Ltd.14.69%176.15%98.45%56.65%418.49%2,332.69%

Performance & Financial Health Analysis: Gland Pharma Ltd. vs Lupin Ltd.

MetricGLANDLUPIN
Market Information
Market Cap i₹295.80B₹1.07T
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i98,0261,119,327
90 Day Avg. Volume i91,7821,057,063
Last Close₹2,210.00₹2,273.10
52 Week Range₹1,573.60 - ₹2,396.00₹1,836.80 - ₹2,494.00
% from 52W High-7.76%-8.86%
All-Time High₹4,350.00 (Aug 09, 2021)₹2,459.00 (May 06, 2026)
% from All-Time High-49.20%-7.56%
Growth Metrics
Quarterly Revenue Growth0.23%0.24%
Quarterly Earnings Growth0.28%0.38%
Financial Health
Profit Margin (TTM) i0.14%0.18%
Operating Margin (TTM) i0.19%0.26%
Return on Equity (TTM) i0.08%0.19%
Debt to Equity (MRQ) i3.1631.51
Cash & Liquidity
Book Value per Share (MRQ)₹580.47₹429.87
Cash per Share (MRQ)₹194.34₹137.55
Operating Cash Flow (TTM) i₹7.50B₹28.04B
Levered Free Cash Flow (TTM) i₹6.99B₹32.82B
Dividends
Last 12-Month Dividend Yield i1.95%0.62%
Last 12-Month Dividend i₹38.00₹12.00

Valuation & Enterprise Metrics Analysis: Gland Pharma Ltd. vs Lupin Ltd.

MetricGLAND (Apr 24, 2026)LUPIN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i34.8622.74
Forward P/E i25.0323.46
PEG Ratio i0.580.60
Price to Sales (TTM) i4.844.03
Price to Book (MRQ) i3.095.37
Market Capitalization
Market Capitalization i₹295.80B₹1.07T
Enterprise Value i₹266.81B₹1.05T
Enterprise Value Metrics
Enterprise to Revenue i4.374.03
Enterprise to EBITDA i18.8015.38
Risk & Other Metrics
Beta i0.410.28
Book Value per Share (MRQ) i₹580.47₹429.87

Financial Statements Comparison: Gland Pharma Ltd. vs Lupin Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricGLAND (2025)LUPIN (2025)
Revenue/Sales i55.84B221.92B
Cost of Goods Sold i20.90B74.56B
COGS % of Revenue i37.4%33.6%
Gross Profit i34.93B147.36B
Gross Margin i62.6%66.4%
Research & Development i332.84MN/A
Operating Income (EBIT) i8.90B43.45B
Operating Margin i15.9%19.6%
EBITDA i14.76B56.45B
EBITDA Margin i26.4%25.4%
Pre-Tax Income i10.63B40.15B
Pre-Tax Income % of Revenue i19.0%18.1%
Income Tax i3.64B7.09B
Income Tax % of Revenue i6.5%3.2%
Net Income (Profit) i6.99B33.06B
Profit Margin i12.5%14.9%

Balance Sheet & Liquidity Metrics

MetricGLAND (2025)LUPIN (2025)
Cash & Equivalents i25.56B19.31B
Total Current Assets i67.83B167.99B
Total Current Assets % of Revenue i121.5%75.7%
Total Current Liabilities i15.65B89.61B
Total Current Liabilities % of Revenue i28.0%40.4%
Long-Term Debt i1.07B20.31B
Long-Term Debt % of Revenue i1.9%9.1%
Total Shareholders Equity i91.51B172.94B
Retained Earnings i71.57B140.71B
Retained Earnings % of Revenue i128.2%63.4%
Property, Plant & Equipment i3.59B84.20M

Cash Flow Statement Comparison

MetricGLAND (2025)LUPIN (2025)
Operating Cash Flow i7.50B28.04B
Operating Cash Flow % of Revenue i13.4%12.6%
Capital Expenditures i-3.84B-16.53B
Free Cash Flow i5.21B13.18B
FCF Margin i9.3%5.9%
Debt Repayment i-628.24M0
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricGLANDLUPIN
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i164.76M457.18M
Float Shares i79.36M241.86M
% Held by Insiders i51.84%47.03%
% Held by Institutions i36.58%34.14%
% Held by Public i11.58%18.83%

Dividend Analysis & Yield Comparison: Gland Pharma Ltd. vs Lupin Ltd.

MetricGLANDLUPIN
Last 12-Month Dividend i₹38.00₹12.00
Last 12-Month Dividend Yield i1.95%0.62%
3-Year Avg Annual Dividend i₹12.67₹8.00
3-Year Avg Dividend Yield i1.00%0.50%
3-Year Total Dividends i₹38.00₹24.00
Ex-Dividend DateAug 14, 2025Jul 25, 2025